secwatch.observer — SEC 8-K summary
======================================

Issuer:     Marker Therapeutics, Inc. (MRKR)
CIK:        0001094038
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001104659-24-089704
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Marker Therapeutics Q2 net loss narrows to $2.2M; reports positive MT-601 APOLLO data, receives $2M NIH grant
--------------------------------------------------------------------------------

- Net loss from continuing ops $2.2M vs $4.1M YoY; cash $7.8M expected to fund into Q4 2025.
- MT-601 APOLLO study shows objective responses in 3 of 3 lymphoma patients; no CRS or ICANS observed.
- Awarded $2M NIH SBIR grant to support MT-601 lymphoma trial.
- MT-401-OTS IND cleared for AML/MDS; clinical program initiation expected Q4 2024.
- R&D expenses $2.3M (flat); G&A decreased to $1.1M from $2.5M YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1094038/000110465924089704/0001104659-24-089704-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1094038/000110465924089704/tm2421372d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-089704

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer